Overview

Sublingual Methadone for the Management of Cancer Breakthrough Pain

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
All
Summary
A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AHS Cancer Control Alberta
Alberta Health Services
Collaborator:
Calgary Health Region
Treatments:
Methadone
Criteria
Inclusion Criteria:

- > 18 years of age

- Experiences episodes of breakthrough pain which respond to opioid therapy

- Controlled baseline pain

- Cognitive status sufficient for accurate completion of assessment form

- Willing to provide written informed consent

- Ability to hold a volume of 1 cc of water under the tongue for 5 minutes

Exclusion Criteria:

- Currently or has received methadone during the previous week

- Recent history of substance abuse

- Severe respiratory impairment or other contraindications to opioids

- Recently received therapies that had the potential to alter pain intensity or response
to analgesics

- Symptomatic anemia